MYC overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression	Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Resistant: C3 – Early Trials tisagenlecleucel-T Resistant : C3	tisagenlecleucel-T Resistant: C3 – Early Trials tisagenlecleucel-T Resistant : C3
MYC overexpression	Mediastinal B Cell Lymphoma	MYC overexpression	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3	lisocabtagene maraleucel Resistant: C3 – Early Trials lisocabtagene maraleucel Resistant : C3
MYC overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression	Diffuse Large B Cell Lymphoma	azacitidine oral Sensitive: C3 – Early Trials azacitidine oral Sensitive : C3	azacitidine oral Sensitive: C3 – Early Trials azacitidine oral Sensitive : C3
MYC overexpression	Cervical Cancer	MYC overexpression	Cervical Cancer	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D
MYC overexpression	Mantle Cell Lymphoma	MYC overexpression	Mantle Cell Lymphoma	TG-1701 Sensitive: D – Preclinical TG-1701 Sensitive : D	TG-1701 Sensitive: D – Preclinical TG-1701 Sensitive : D
MYC overexpression	Multiple Myeloma	MYC overexpression	Multiple Myeloma	bortezomib Resistant: D – Preclinical bortezomib Resistant : D	bortezomib Resistant: D – Preclinical bortezomib Resistant : D
MYC overexpression	Thyroid Gland Carcinoma	MYC overexpression	Thyroid Gland Carcinoma	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D
MYC overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression	Diffuse Large B Cell Lymphoma	INCB57643 Sensitive: D – Preclinical INCB57643 Sensitive : D	INCB57643 Sensitive: D – Preclinical INCB57643 Sensitive : D
MYC overexpression	Mantle Cell Lymphoma	MYC overexpression	Mantle Cell Lymphoma	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D	venetoclax Sensitive: D – Preclinical venetoclax Sensitive : D
MYC overexpression	Gastric Cancer	MYC overexpression	Gastric Cancer	WB100 Sensitive: D – Preclinical WB100 Sensitive : D	WB100 Sensitive: D – Preclinical WB100 Sensitive : D
MYC overexpression	Pancreatic Ductal Adenocarcinoma	MYC overexpression	Pancreatic Ductal Adenocarcinoma	WB100 Sensitive: D – Preclinical WB100 Sensitive : D	WB100 Sensitive: D – Preclinical WB100 Sensitive : D
MYC overexpression	Acute Myelogenous Leukemia	MYC overexpression	Acute Myelogenous Leukemia	WB100 Sensitive: D – Preclinical WB100 Sensitive : D	WB100 Sensitive: D – Preclinical WB100 Sensitive : D
MYC overexpression	Non Small Cell Lung Cancer	MYC overexpression	Non Small Cell Lung Cancer	MRT-2359 Sensitive: D – Preclinical MRT-2359 Sensitive : D	MRT-2359 Sensitive: D – Preclinical MRT-2359 Sensitive : D
MYC overexpression	Non Small Cell Lung Cancer	MYC overexpression	Non Small Cell Lung Cancer	ROS1 inhibitor Resistant: D – Preclinical ROS1 inhibitor Resistant : D	ROS1 inhibitor Resistant: D – Preclinical ROS1 inhibitor Resistant : D
MYC overexpression	Lymphoma	MYC overexpression	Lymphoma	brusatol Sensitive: D – Preclinical brusatol Sensitive : D	brusatol Sensitive: D – Preclinical brusatol Sensitive : D
MYC overexpression	Triple Negative Breast Cancer	MYC overexpression	Triple Negative Breast Cancer	PD-L1 inhibitor + MYC inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + MYC inhibitor Sensitive : D	PD-L1 inhibitor + MYC inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + MYC inhibitor Sensitive : D
MYC overexpression	Hepatocellular Cancer	MYC overexpression	Hepatocellular Cancer	HX301 Sensitive: D – Preclinical HX301 Sensitive : D	HX301 Sensitive: D – Preclinical HX301 Sensitive : D
MYC overexpression	Small Cell Lung Cancer	MYC overexpression	Small Cell Lung Cancer	ICX-101 Sensitive: D – Preclinical ICX-101 Sensitive : D	ICX-101 Sensitive: D – Preclinical ICX-101 Sensitive : D

MYC overexpression

Associations